European Journal of Internal Medicine
Volume 19, Issue 4 , Pages 266-270 , June 2008

Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin

  • Ioannis S. Elefsiniotis

      Affiliations

    • Department of Internal Medicine, Hepatology Unit, Hippokration Hospital, Athens, Greece
    • Corresponding Author InformationCorresponding author. Carchidonos 9, A. Glyfada, 16562 Greece. Tel.: +30 2109630312.
    • ,
  • Christos Pavlidis

      Affiliations

    • Reference Center for Viral Hepatitis, I.K.A, Athens, Greece
    • ,
  • Ioannis Ketikoglou

      Affiliations

    • Department of Internal Medicine, Hepatology Unit, Hippokration Hospital, Athens, Greece
    • ,
  • Sotirios Koutsounas

      Affiliations

    • Reference Center for Viral Hepatitis, I.K.A, Athens, Greece
    • ,
  • Nikolaos Scarmeas

      Affiliations

    • Taub Institute, Columbia University Medical Center, New York, USA
    • ,
  • Konstantinos D. Pantazis

      Affiliations

    • Department of Internal Medicine, Hepatology Unit, Hippokration Hospital, Athens, Greece
    • ,
  • Antonios Moulakakis

      Affiliations

    • Department of Internal Medicine, Hepatology Unit, Hippokration Hospital, Athens, Greece
    • ,
  • Epameinondas V. Tsianos

      Affiliations

    • First Division of Internal Medicine, Hepatogastroenterology Unit, Medical School, University of Ioannina, Greece

Received 28 September 2006 ,Revised 17 March 2007 ,Accepted 12 June 2007.

References 

  1. Mc Hutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–1492
  2. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology. 1996;111:1307–1312
  3. NIH Consensus Statement on Management of Hepatitis . NIH Consens. State Science Statements. 2002;19(3):1–46June 10–12, 2002
  4. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon a-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med. 2004;140:346–355
  5. Manns MP, Mc Hutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  7. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  8. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  9. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology. 2002;36:729–736
  10. Gasteyger C, Tremblay A. Metabolic impact of body fat distribution. J Endocrinol Invest. 2002;25:876–883
  11. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. 2003;98:2064–2071
  12. Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol. 2006;21:1266–1268
  13. Mc Hutchinson JG, Manns MP, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069
  14. Davis GL, Wong JB, Mc Hutchinson JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–652
  15. Manns MP. Adhérence to combination therapy: influence on sustained virological response and economic impact. Gastroenterol Clin North Am. 2004;33(1 suppl.):s11–s24
  16. Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon alpha2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat. 2005;12:380–385
  17. Hasan F, Asker B, AI-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004;99:1733–1737
  18. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003;37:600–609
  19. Alessi N, Freni MA, Spadaro A, Ajello A, Turiano S, Migliorato D, et al. Efficacy of interferon treatment in elderly patients with chronic hepatitis C. Infez Med. 2003;11:208–212

PII: S0953-6205(07)00353-6

doi: 10.1016/j.ejim.2007.06.014

European Journal of Internal Medicine
Volume 19, Issue 4 , Pages 266-270 , June 2008

Article Tools